Bristol Myers Squibb Beyond the Patent Cliff | Business and Finance News

Bristol Myers Squibb’s future looks brighter than the patent cliff suggests—while Eliquis’ loss in 2028 and declining sales of older drugs raise eyebrows, half their revenue now comes from hot new drugs like Breyanza and Camzyos. With a robust pipeline including two promising multiple myeloma treatments and key upcoming trial results, the company’s stock is undervalued relative to future earnings and offers a solid dividend. Investors like Israel Englander are betting on the long game, showing that looking past short-term worries can reveal major upside. Listen in comfort:Get a discount on a Soli Pillow: http://solipillow.com/discount/dnn. Advertise on DNN:[email protected] This is an automated, high-level news summary based on public reporting.Report issues to [email protected]. View sources & latest updates:https://sources.thednn.ai/a4a4378ec5bd976f